MedTrace Logo

Study of the Efficacy and Safety of Granexin® Gel to Improve Burn Wound Healing

NCT04684121 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2023-06-22

No results posted yet for this study

Summary

To evaluate the efficacy of Granexin® gel to promote accelerated healing of second-degree (deep partial thickness) thermal burns.

Conditions

  • Second Degree Burn
  • Thermal Burn

Interventions

DRUG

Granexin® gel (200 μM)

Granexin® gel (200 μM) will be topically applied once daily for 10 days in association with standard of care (SOC) wound cleaning and ACTICOAT Flex 3TM dressing.

DRUG

Vehicle gel

Vehicle gel will be topically applied once daily for 10 days in association with standard of care (SOC) wound cleaning and ACTICOAT Flex 3TM dressing.

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • Xequel Bio, Inc.

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-01
Primary Completion
2024-08-01
Completion
2024-08-01
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04684121 on ClinicalTrials.gov